Gcsf ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

---

Clinical trials : 482 /  Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03547830 (ClinicalTrials.gov)	April 13, 2019	24/5/2018	Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients	A Clinical Trial of Plerixafor With G-CSF as Additional Agents in Conditioning Regimen for Prevention of Graft Failure in Patients With Chronic Granulomatous Disease	Chronic Granulomatous Disease	Drug: Plerixafor;Drug: Gcsf	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	NULL	Recruiting	1 Month	24 Years	All	17	Phase 2	Russian Federation
2	NCT00176852 (ClinicalTrials.gov)	June 2002	12/9/2005	Stem Cell Transplant for Hemoglobinopathy	Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism	Sickle Cell Disease;Thalassemia;Severe Congenital Neutropenia;Diamond-Blackfan Anemia;Shwachman-Diamond Syndrome	Drug: Busulfan, Fludarabine, ATG, TLI;Drug: Busulfan, Cyclophosphamide, ATG, GCSF;Drug: Campath, Fludarabine, Cyclophosphamide;Radiation: Total Body Irradiation;Procedure: Stem cell infusion	Masonic Cancer Center, University of Minnesota	National Marrow Donor Program	Completed	N/A	50 Years	All	22	Phase 2/Phase 3	United States